---
title: "Lakefront Biotherapeutics NV (LKFT.US)"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/LKFT.US.md"
symbol: "LKFT.US"
name: "Lakefront Biotherapeutics NV"
industry: "生物技术"
datetime: "2026-05-16T03:56:37.120Z"
locales:
  - [en](https://longbridge.com/en/quote/LKFT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LKFT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LKFT.US.md)
---

# Lakefront Biotherapeutics NV (LKFT.US)

## 公司概况

Lakefront Biotherapeutics NV 是一家生物技术公司，主要在美国和欧洲开发专注于肿瘤学和免疫学的药物。该公司的产品管线包括 GLPG3667，目前正在进行皮肌炎和系统性红斑狼疮的二期临床试验；GLPG5101，一种在护理现场制造的 CD19 CAR-T 候选产品，目前正在进行复发/难治性非霍奇金淋巴瘤的一期/二期试验；以及 GLPG5301，一种在护理现场制造的 BCMA CAR-T 候选产品，目前正在进行复发/难治性多发性骨髓瘤的一期/二期试验。该公司与吉利德科学公司（Gilead Sciences, Inc.）有合作协议。该公司曾名为 Galapagos NV，并于 2026 年 5 月更名为 Lakefront Biotherapeutics NV

| 项目 | 详情 |
|------|--------|
| 行业 | 生物技术 |
| 交易所 | US Market |
| 官网 | [lakefrontbio.com](https://lakefrontbio.com) |

## 关键驱动因素
> *AI 分析的影响该股票表现的关键因素*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Longbridge 独家多因子评级模型*
> 更新时间: 2026-05-15T04:30:16.000Z

**综合: B (0.32)**

**行业**: 生物技术

| 指标 | 数值 |
|--------|-------|
| 行业排名 | 35 / 390 |
| 行业中位数 | C |
| 行业均值 | C |

- **风格**: 平衡型 - 公司有成长期业务也有成熟期业务的股票。
- **规模**: 中盘型 - 公司经营兼顾大盘股的稳定性和小盘股的高收益。

**综合评分**: B

#### 风格得分 评分: 

| 指标 | 数值 | 评级 |
|-----------|-------|--------|
| 营业收入同比 | 292.86% |  |
| 净利润同比 | 412.73% |  |
| 市净率 | 0.49 |  |
| 股息率 | 0.00% |  |

#### 规模得分 评分: 

| 指标 | 数值 | 评级 |
|-----------|-------|--------|
| 市值 | 1811510481.79 |  |
| 营业收入 | 1219200793.54 |  |

#### 多维评分 评分: B

| 指标 | 数值 | 评级 |
|-----------|-------|--------|
| 净资产收益率（ROE） | 16.26% | A |
| 净利率 | 46.83% | A |
| 毛利率 | -451.78% | E |
| 营业收入同比 | 292.86% | A |
| 净利润同比 | 412.73% | A |
| 总资产同比 | -11.23% | E |
| 净资产同比 | 25.34% | A |
| 现金流净利率 | -61.70% | E |
| 运营现金流同比 | 292.86% | A |
| 资产周转率 | 0.28 | D |
| 资产负债率 | 3.53% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Lakefront Biotherapeutics NV",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "风格得分",
      "grade": "",
      "indicators": [
        {
          "name": "营业收入同比",
          "value": "292.86%",
          "rating": ""
        },
        {
          "name": "净利润同比",
          "value": "412.73%",
          "rating": ""
        },
        {
          "name": "市净率",
          "value": "0.49",
          "rating": ""
        },
        {
          "name": "股息率",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "规模得分",
      "grade": "",
      "indicators": [
        {
          "name": "市值",
          "value": "1811510481.79",
          "rating": ""
        },
        {
          "name": "营业收入",
          "value": "1219200793.54",
          "rating": ""
        }
      ]
    },
    {
      "name": "多维评分",
      "grade": "B",
      "indicators": [
        {
          "name": "净资产收益率（ROE）",
          "value": "16.26%",
          "rating": "A"
        },
        {
          "name": "净利率",
          "value": "46.83%",
          "rating": "A"
        },
        {
          "name": "毛利率",
          "value": "-451.78%",
          "rating": "E"
        },
        {
          "name": "营业收入同比",
          "value": "292.86%",
          "rating": "A"
        },
        {
          "name": "净利润同比",
          "value": "412.73%",
          "rating": "A"
        },
        {
          "name": "总资产同比",
          "value": "-11.23%",
          "rating": "E"
        },
        {
          "name": "净资产同比",
          "value": "25.34%",
          "rating": "A"
        },
        {
          "name": "现金流净利率",
          "value": "-61.70%",
          "rating": "E"
        },
        {
          "name": "运营现金流同比",
          "value": "292.86%",
          "rating": "A"
        },
        {
          "name": "资产周转率",
          "value": "0.28",
          "rating": "D"
        },
        {
          "name": "资产负债率",
          "value": "3.53%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## 估值分析

| 指标 | 当前值 | 行业排名 | 最高 | 中位 | 最低 |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 3.12 | 12/390 | - | - | - |
| PB | 0.48 | 39/390 | - | - | - |
| PS (TTM) | 1.46 | 34/390 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## 同业比较

| 排名 | 名称 | 盈利 | 成长 | 运营 | 财务安全 | 现金流 | 评级 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel制药 (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## 机构观点

### 分析师评级分布

> 截至 2026-05-12T04:00:00.000Z

分析师总数: **4**

| 评级 | 数量 | 占比 |
|--------|-------|-----------| 
| Hold | 3 | 75% |

### 目标价预测

| 指标 | 价格 |
|--------|-------|
| 当前价格 | 25.50 |
| 最高目标价 | undefined |
| 最低目标价 | undefined |

## 参考链接

- [公司概况 — 简介、高管、股东、业务构成](https://longbridge.com/zh-CN/quote/LKFT.US/overview.md)
- [财务报表 — 利润表、资产负债表、现金流、分红方案](https://longbridge.com/zh-CN/quote/LKFT.US/norm.md)
- [相关新闻](https://longbridge.com/zh-CN/quote/LKFT.US/news.md)
- [公告 — 公司公告与监管文件](https://longbridge.com/zh-CN/quote/LKFT.US/filings.md)

---

> **免责声明: 本文仅供参考，不构成任何投资建议。**